Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “buy” rating reaffirmed by stock analysts at Piper Jaffray Companies in a report released on Thursday. They currently have a $24.00 price objective on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ target price would indicate a potential upside of 39.45% from the stock’s previous close.

Other analysts have also recently issued reports about the company. Needham & Company LLC lifted their price target on Collegium Pharmaceutical from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday. They noted that the move was a valuation call. HC Wainwright assumed coverage on Collegium Pharmaceutical in a report on Monday, September 11th. They set a “buy” rating and a $21.00 price target for the company. Jefferies Group lifted their price target on Collegium Pharmaceutical to $27.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Zacks Investment Research raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a report on Monday, August 14th. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $23.50.

Shares of Collegium Pharmaceutical (NASDAQ COLL) opened at $17.21 on Thursday. Collegium Pharmaceutical has a 52-week low of $7.37 and a 52-week high of $20.92.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.73) by $0.28. The company had revenue of $11.95 million during the quarter, compared to analysts’ expectations of $5.31 million. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The business’s revenue was up 2814.6% on a year-over-year basis. During the same period last year, the firm posted ($1.13) earnings per share. equities analysts expect that Collegium Pharmaceutical will post -2.56 EPS for the current fiscal year.

In other Collegium Pharmaceutical news, CTO Alison B. Fleming sold 4,029 shares of the firm’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $17.00, for a total transaction of $68,493.00. Following the transaction, the chief technology officer now owns 28,513 shares in the company, valued at approximately $484,721. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Michael Thomas Heffernan sold 50,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total value of $776,500.00. Following the transaction, the chief executive officer now owns 558,987 shares in the company, valued at approximately $8,681,068.11. The disclosure for this sale can be found here. Over the last three months, insiders have sold 58,630 shares of company stock valued at $924,360. 25.76% of the stock is currently owned by insiders.

A number of institutional investors have recently bought and sold shares of the business. Sectoral Asset Management Inc increased its stake in Collegium Pharmaceutical by 41.4% during the 2nd quarter. Sectoral Asset Management Inc now owns 1,808,750 shares of the specialty pharmaceutical company’s stock worth $22,627,000 after acquiring an additional 529,503 shares during the period. Macquarie Group Ltd. increased its stake in Collegium Pharmaceutical by 18.9% during the 3rd quarter. Macquarie Group Ltd. now owns 1,329,979 shares of the specialty pharmaceutical company’s stock worth $13,951,000 after acquiring an additional 211,288 shares during the period. Vanguard Group Inc. increased its stake in Collegium Pharmaceutical by 7.8% during the 1st quarter. Vanguard Group Inc. now owns 806,539 shares of the specialty pharmaceutical company’s stock worth $8,113,000 after acquiring an additional 58,398 shares during the period. Prudential Financial Inc. increased its stake in Collegium Pharmaceutical by 62.8% during the 3rd quarter. Prudential Financial Inc. now owns 557,050 shares of the specialty pharmaceutical company’s stock worth $5,843,000 after acquiring an additional 214,860 shares during the period. Finally, Citadel Advisors LLC increased its stake in Collegium Pharmaceutical by 773.8% during the 3rd quarter. Citadel Advisors LLC now owns 544,033 shares of the specialty pharmaceutical company’s stock worth $5,707,000 after acquiring an additional 481,771 shares during the period. Hedge funds and other institutional investors own 79.98% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Piper Jaffray Companies Reaffirms “Buy” Rating for Collegium Pharmaceutical (COLL)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/12/07/piper-jaffray-companies-reaffirms-buy-rating-for-collegium-pharmaceutical-coll.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Stock Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.